The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


The Board
Advisory Board
The Board

The Academy is Governed by a Board of 8 Directors, the board is comprised of APS members who are elected by the membership and give their time and expertise free of charge.
The Board
Ms Helen Barker
Helen is the managing director of Project-ion Ltd. and program manager in infectious diseases at the University of Oxford. She is an experienced project director in the strategic and technical development of a broad portfolio of R&D programs. Helen joined the APS in 2001 and the New Scientists Focus Group shortly after. Elected on to the board in 2008, she was appointed APS Chief Scientist in 2012. Graduating from the University of Sunderland in Chemical and Pharmaceutical Science, Helen worked for Bristol-Myers Squibb, primarily developing analytical methods for API and drug product. Subsequently gaining over 15 years of experience working for Pfizer, Helen developed a range of solid, liquid and inhaled programs. Broadening experience across the Pharmaceutical Sciences and R&D, through successful delivery of projects and initiatives, Helen developed innovative strategies and led global multidisciplinary program teams, both in CMC and pan-R&D. Therapeutic areas of key experience include infectious and respiratory diseases. Research areas include modernizing medical microbiology with genetics, reactions in the solid state, predictive models and intelligent software. Core interests include development of novel healthcare concepts, business and program development, supporting emerging Pharmaceutical Scientists and engaging key opinion leaders.
Dr Julie Cahill
Julie is Director, Product Development at AstraZeneca R&D.
Dr Geoff Davison
Geoff is CEO of Bionow the membership organisation for life science businesses in the North of England. Prior to this Geoff was founder and Technical Director of Biorite Ltd and Advanced Biomedical Ltd both spin-out companies from the University of Manchester. Geoff has a degree in Biochemistry and a PhD from the School of Pharmacy, University of Manchester where he began his career undertaking postdoctoral research.
Prof Jayne Lawrence
Jayne is Professor and Head of the Pharmaceutical Biophysics Group. She is currently on a 50% secondment at the Royal Pharmaceutical Society (RPS) as their Chief Scientist. At the RPS Jayne is responsible for science and research, performing a variety of roles including working with other scientific organisations and the media and ensuring that the RPS and its membership is up to date with the latest scientific developments in pharmacy. This is a role she has performed since 2007. At King’s, Jayne’s research has focussed on improving the delivery of low molecular weight drugs and biomolecules such as DNA and siRNA using a range of novel and conventional surfactant/polymer and lipid molecules. Jayne is particularly interested in understanding how the structure of a molecule influences the molecular architecture of the delivery vehicle it forms and its fate in the target cell. To achieve these aims Jayne uses a range of advanced analytical techniques including light and neutron scattering and reflectivity. Jayne sits on a number of national committees including the Academy of Pharmaceutical Sciences (Vice-Chair), the United Kingdom and Ireland Controlled Release Society (Treasurer) and the Joint Pharmaceutical Analysis Group, the Institute of Physics and Royal Society of Chemistry’s Joint Neutron Group. She has recently been appointed Vice-Chair of the Formulation and Pharmaceutical Technology Special Interest Group for the International Pharmaceutical Federation. Jayne is a pharmacist, having completed a BSc in Pharmacy at Liverpool Polytechnic and undertaken a year’s pre-registration training in community and industrial pharmacy. After qualifying as a pharmacist Jayne undertook a PhD at Manchester University under the supervision of Professors Peter Elworthy and David Attwood. Jayne started her academic career as a lecturer in Pharmacy at Chelsea College, which subsequently merged with King’s College. Jayne has spent sabbaticals working in the pharmaceutical industry and retains excellent links with the industry.
Dr Michael Leane
Michael Leane is a Principal Scientist with Bristol-Myers Squibb.  He graduated with a Pharmacy degree from Trinity College Dublin and has a PhD in Advanced Drug Delivery from the University of Nottingham.  He has previously worked at Elan Pharmaceutical Technologies focusing primarily on the development of new solid dosage form delivery systems for poorly permeable drugs and at Phaeton Research investigating novel gastroretentive platforms.  He joined Bristol-Myers Squibb in 2005, with an initial role as formulation scientist leading a team concentrating on development of a poorly-soluble compound.  His current role at BMS is within drug product development where he specialises in the optimisation of API particle properties to facilitate drug product manufacture.     He is a committee member and former chair of the APS Materials Science Focus Group and has authored and co-authored a number of publications around amorphous formulation development and novel characterisation techniques.  He is co-lead of an APS-sponsored working group aiming to establish a Manufacturing Classification System for oral solid dosage forms.  This initiative developed from an APS conference in 2013 and has grown through the publication of a peer-reviewed position paper and interaction with other international pharmaceutical science bodies such as the AAPS and APV.
Dr Mark McAllister
Dr Mark McAllister is a team leader in the Research Formulation group of Pfizer, PGRD, in Sandwich, UK. He graduated in Pharmacy from Queens University Belfast in 1990 and completed an industrial/hospital pre-registation year before commencing a PhD programme (development of liposomal polymyxin for the treatment of cystic fibrosis) at Aston University with Prof. Oya Alpar. His first industrial appointment at Hoechst-Roussel, Swindon, provided experience working with silicone-based hormone sustained-release. Mark moved to SmithKline Beecham in 1995 where he gained experience in drug absorption profiling, biopharmaceutics and early phase candidate assessment. As a manager within the Strategic Technologies department of GlaxoSmithKline Pharmaceutical Development in Harlow, he was responsible for a number of technology development programmes spanning areas such as oral modified-release and bioenhancement. Since joining Pfizer in 2008, he has continued his research interests in biopharmaceutics and provides formulation support for programmes from early discovery through to proof-of-concept stage.
Prof Yvonne Perrie
Professor Yvonne Perrie is Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Scotland. She has a BSc (First-Class Hons) in Pharmacy from Strathclyde University, and a PhD from the University of London under the supervision of Prof Gregoriadis. Yvonne’s research is multi-disciplinary and focused on the development of drug carrier systems for the delivery of drugs and vaccines. Yvonne is Editor-in-Chief of the Journal of Liposome Research and Pharmaceutics and Associate Editor for the Journal of Drug Targeting and the Journal of Pharmacy and Pharmacology.
Dr John Wahlich
John is a consultant in the pharmaceutical sciences with over 30 years’ experience in product development. John is a chemist by training (PhD from Nottingham School of Pharmacy) and has analytical and formulation expertise gained from leadership roles in product line extensions, physical properties and early stage development in GlaxoSmithKline

APS Scientific Administrator:
Dr Carol O'Connor
Carol has over 20 years drug development, managerial and project management experience working in the biotechnology, pharmaceutical and device industries. She is a registered Pharmacist with a PhD from the University of Manchester, in controlled drug release Her background is in pharmaceutical development and CMC regulatory affairs with scientific and technical knowledge in drug delivery combined with business and commercial skills. This she has gained from a career working for initially Fisons and then Astra Zeneca in Pharmaceutical development and project management. Moving into Programme Management with Quadrant Healthcare working with novel particle technologies and biologicals, with a range of partnering companies. She is currently a consultant, involved in a range of projects at all stages of drug development, for in house development and partnering from small start-up companies to multinational companies.

APS Secretariat:
Mr Chris Barron
Chris is Client Relationship Manager at AssociAction Enterprises - the APS Secretariat. Chris has extensive knowledge of a wide range of events gained over many years in the entertainment and events business. Chris is also an experienced manager in IT and Resources.
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.